Russell Investments Group Ltd. Sells 32,970 Shares of Integra LifeSciences Holdings Corporation $IART

Russell Investments Group Ltd. cut its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 30.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,920 shares of the life sciences company’s stock after selling 32,970 shares during the quarter. Russell Investments Group Ltd. owned 0.10% of Integra LifeSciences worth $1,669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Assenagon Asset Management S.A. lifted its position in Integra LifeSciences by 2,418.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company’s stock valued at $39,581,000 after purchasing an additional 1,728,480 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its position in Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock valued at $32,457,000 after purchasing an additional 901,600 shares during the last quarter. Soleus Capital Management L.P. bought a new stake in Integra LifeSciences during the fourth quarter valued at approximately $28,940,000. Charles Schwab Investment Management Inc. lifted its position in Integra LifeSciences by 9.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,146,921 shares of the life sciences company’s stock valued at $25,221,000 after purchasing an additional 99,348 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Integra LifeSciences by 9.9% during the fourth quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company’s stock valued at $20,240,000 after purchasing an additional 80,090 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Up 3.4%

Shares of NASDAQ IART opened at $14.76 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. Integra LifeSciences Holdings Corporation has a 52 week low of $11.06 and a 52 week high of $27.13. The firm’s fifty day moving average is $12.86 and its 200 day moving average is $16.23. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -2.26, a PEG ratio of 0.80 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same period in the previous year, the firm earned $0.63 earnings per share. The firm’s revenue for the quarter was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on IART. Wells Fargo & Company lowered their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. JMP Securities lowered their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a report on Friday, May 9th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.